Branded Generics Market by Products (Value-added & Trade Named Generics), Applications (Cardiovascular, Anti-cancer, CNS, and Anti-infective), Distribution Channels (Hospital Pharmacy, Clinics, Pharmacy, and Drug Stores), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global branded generics market size is expected to register a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the introduction of new medical practices and entry of new market players.
Branded generics are types of generic drugs whose names are assigned by the original drug manufacturing company rather than focusing on the chemical name of the drugs components. These types of drugs are primarily developed by the original drug developer after the expiration of drugs patent and the branded name of the drugs remained under the control of the original company. However, generic drugs can be available in different brand names but they normally have the same chemical components or active ingredients with the branded drug. Various extrinsic dynamics and internal relating to marketing, manufacturing, and licensing characterize the pharmaceutical industry, which presents a key aspect for the market expansion.
Branded drugs refers to patented drugs, which is the result of pharmaceutical company filing for a patent when they discover new drug. Branded generics are versions of products sold by manufacturers that build brand for their generic segments. These generics drugs are also referred to as value-added generics and are different from commodity generics of pharmaceutical products. These drugs are mainly used as a substitute to innovative products when the patent expires.
Market Trends, Drivers, Restraints, and Opportunities
- Large development of pharmaceutical products and increasing cases of patent drugs for several diseases are expected to boost the market growth in the coming years.
- Favorable marketing authorization procedures for pharmaceutical products and entry of several new players in the market present key aspects for the market growth.
- New clinical practices, changing medical practices, and large profit margin are some other main factors which are further projected to accelerate the market development.
- Advancement of innovative pharmaceutical technology and massive R&D activities are key factors, which are expected to offer lucrative opportunities for the market expansion in the near future.
- Wide availability of commodity generic products is a key challenge that can restrain the market expansion.
Scope of the Report
The report on the global branded generics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Branded Generics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Products (Value-added & Trade Named Generics), Applications (Cardiovascular, Anti-cancer, CNS, and Anti-infective), Distribution Channels (Hospital Pharmacy, Clinics, Pharmacy, and Drug Stores) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Bausch Health; Mylan N.V.; Cadila Healthcare; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Apotex Inc.; Bausch Health; Cadila Healthcare; Sandoz Private Limited; GlaxoSmithKline Pharmaceuticals Limited; AstraZeneca plc.; Par Pharmaceutical Companies, Inc.; Lupin Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd. |
Market Segment Insights
Value-added & trade named generics segment is expected to grow at a rapid pace
Based on products, the global branded generics market consists of value-added & trade named generics. The value-added & trade named generics segment accounted for a key share of the market in 2020 and is expected to grow at a rapid pace due to large number of pharmaceutical products and increasing competition for advancement of highly effective generic drugs.
Cardiovascular segment is projected to expand at a considerable CAGR
On the basis of applications, the market is divided into cardiovascular, anti-cancer, CNS, and anti-infective. The cardiovascular (CVS) segment is projected to expand at a considerable CAGR during the forecast period due to rising cases of the expiry of CVS drugs patents and increasing demand for effective treatment of heart-related diseases. Meanwhile, the CNS segment is anticipated to expand at substantial growth during the forecast period owing to growth of patent expiry of several key antipsychotics and antidepressants.
Hospital pharmacy segment is expected to expand at a robust growth rate
Based on distribution channels, the global branded generics market is divided into hospital pharmacy, clinics, pharmacy, and drug stores. The hospital pharmacy segment is expected to expand at a robust growth rate during the projected period due to wide availability of innovative pharmaceutical products in hospital pharmacies. On the other hand, the clinics segment is anticipated to expand at a rapid pace during the forecast period due to increasing number of patients visit in clinics due to easy accessibility and low cost.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the targeted period due to the increasing demand for cost-effective medicines and early adoption of advanced methods for drug discovery in the region. The market of Asia Pacific, however, is anticipated to exhibit a healthy growth rate during the forecast period owing to increasing healthcare infrastructure and government funding in the region.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Branded Generics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Branded Generics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Branded Generics Market - Supply Chain
4.5. Global Branded Generics Market Forecast
4.5.1. Branded Generics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Branded Generics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Branded Generics Market Absolute $ Opportunity
5. Global Branded Generics Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Branded Generics Market Size and Volume Forecast by Applications
5.3.1. Cardiovascular
5.3.2. Anti-cancer
5.3.3. CNS
5.3.4. Anti-infective
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Branded Generics Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Branded Generics Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Branded Generics Demand Share Forecast, 2019-2026
7. North America Branded Generics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Branded Generics Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Branded Generics Market Size and Volume Forecast by Applications
7.4.1. Cardiovascular
7.4.2. Anti-cancer
7.4.3. CNS
7.4.4. Anti-infective
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Branded Generics Demand Share Forecast, 2019-2026
8. Latin America Branded Generics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Branded Generics Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Branded Generics Market Size and Volume Forecast by Applications
8.4.1. Cardiovascular
8.4.2. Anti-cancer
8.4.3. CNS
8.4.4. Anti-infective
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Branded Generics Demand Share Forecast, 2019-2026
9. Europe Branded Generics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Branded Generics Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Branded Generics Market Size and Volume Forecast by Applications
9.4.1. Cardiovascular
9.4.2. Anti-cancer
9.4.3. CNS
9.4.4. Anti-infective
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Branded Generics Demand Share Forecast, 2019-2026
10. Asia Pacific Branded Generics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Branded Generics Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Branded Generics Market Size and Volume Forecast by Applications
10.4.1. Cardiovascular
10.4.2. Anti-cancer
10.4.3. CNS
10.4.4. Anti-infective
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Branded Generics Demand Share Forecast, 2019-2026
11. Middle East & Africa Branded Generics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Branded Generics Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Branded Generics Market Size and Volume Forecast by Applications
11.4.1. Cardiovascular
11.4.2. Anti-cancer
11.4.3. CNS
11.4.4. Anti-infective
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Branded Generics Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Branded Generics Market: Market Share Analysis
12.2. Branded Generics Distributors and Customers
12.3. Branded Generics Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bausch Health
12.4.2. Mylan N.V.
12.4.3. Cadila Healthcare
12.4.4. Hospira Inc.
12.4.5. Dr. Reddy’s Laboratories Ltd.
12.4.6. Apotex Inc.
12.4.7. Bausch Health
12.4.8. Cadila Healthcar
Segments Covered in the Report
The global branded generics market has been segmented on the basis of
Products
- Value-added & Trade Named Generics
Applications
- Cardiovascular
- Anti-cancer
- CNS
- Anti-infective
Distribution Channels
- Hospital Pharmacy
- Clinics
- Pharmacy
- Drug Stores
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bausch Health
- Mylan N.V.
- Cadila Healthcare
- Hospira Inc.
- Dr. Reddy’s Laboratories Ltd.
- Apotex Inc.
- Bausch Health
- Cadila Healthcare
- Sandoz Private Limited
- GlaxoSmithKline Pharmaceuticals Limited
- AstraZeneca plc.
- Par Pharmaceutical Companies, Inc.
- Lupin Pharmaceuticals, Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Key players competing in the global branded generics market are Bausch Health; Mylan N.V.; Cadila Healthcare; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Apotex Inc.; Bausch Health; Cadila Healthcare; Sandoz Private Limited; GlaxoSmithKline Pharmaceuticals Limited; AstraZeneca plc.; Par Pharmaceutical Companies, Inc.; Lupin Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd. The main market players are continuously engaged in a range of the market development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market share in the long run.
Our Clients
Related Reports
Some other reports from this category!
